ArticleFrontiers in endocrinology2026
MCM8 variants in two patients with primary ovarian insufficiency: clinical findings and
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: Pediatric-onset primary ovarian insufficiency (POI) presents distinct clinical challenges, including delayed puberty or growth retardation. Previously, we reported a Chinese family with POI harboring compound heterozygous variants (p.C242R and p.S445*) in Objective: This study describes clinical findings of pediatric-onset POI patients with compound heterozygous Methods: HeLa cell models were used to overexpress double-mutant (p.C242R and p.S445*) or wild-type MCM8. Functional consequences were evaluated using immunofluorescence staining, flow cytometry, and western blotting to assess DNA damage repair, cell cycle and apoptosis. Co-immunoprecipitation coupled with mass spectrometry (CoIP-MS/MS) was used to screen the disrupted protein interactome. Cut&Tag and mRNA-seq analyses were used to examine chromatin-binding-associated changes and transcriptomic alterations. Results: Ovarian tissues from POI patients exhibited reduced MCM8 expression and increased apoptosis. Cells expressing the artificial double-mutant MCM8 construct showed delayed resolution of DNA damage, as indicated by persistent γ-H2AX accumulation, and altered recruitment of DMC1 and RAD51. These changes were accompanied by S-phase accumulation and increased apoptosis. CoIP-MS/MS analysis identified altered interaction between double-mutant MCM8 and MCM6, suggesting possible changes in replication-associated protein interactions. Integrated CUT&Tag and RNA-seq analyses identified MCM8-associated chromatin-binding changes and transcriptomic alterations involving candidate genes enriched in ovarian survival and metabolic pathways, including the PI3K/AKT signaling pathway. Conclusions: These specific
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.